Expo Hub
55 min
Webinar

The changing prostate panorama: 18F-Fluciclovine and its role in biochemically recurrent prostate cancer

About the session

Join Dr. Hollie Lai as she discusses challenges associated with PET/CT imaging in pediatric patients. This hour-long webinar provides an in-depth review of the physiologic uptake in areas that differ from imaging adults, how to identify the differences, and what can be done to improve overall image quality when scanning pediatric patients.

Nuclear Medicine

Indication
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.


Important safety information 

  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended. 
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available. 
  • Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers. Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Dosage forms and strengths 
Injection: supplied as a clear, colorless solution in a 30 mL multiple-dose vial containing 335 to 8200 MBq/mL (9 to 221 mCi/mL) fluciclovine F 18 at calibration time and date. 
For full prescribing information, visit www.Axumin.com